CAR-T in Lymphoma: Lessons from Everyday Practice

Live online webinar · 90 minutes · English

A panel of experts from Stockholm shares their everyday clinical experience in treating lymphoma patients with CAR-T therapies – from patient qualification and referral, through bridging therapy and toxicity management, to long-term follow-up.

The webinar takes the form of an expert discussion. Questions are displayed on screen, and the panelists answer them based on their own clinical practice, supported by their own slides where relevant. The session closes with an extended live Q&A with the audience.

Date and time

11 November 2026
15:00–16:30 CET (Sweden, Poland, Czech Republic, Hungary, Austria)
16:00–17:30 EET (Romania, Greece)

Experts

• Prof. Stephan Mielke
• Sólveig Adalsteinsdóttir
• Ksenia Boriskina
• Teng Wang

Karolinska University Hospital, Stockholm, Sweden

Programme

Welcome and introduction

1. Patient qualification & decision-making
Clinical criteria for CAR-T qualification, treatment decision-making, and the role of the multidisciplinary tumour board.

2. Referral pathway & centre network
The referral process and centre network, factors affecting the time from referral to infusion, patient preparation, and communication with referring centres.

3. Bridging therapy
The choice of bridging therapy in aggressive lymphoma and the management of disease progression during bridging.

4. Toxicity management
The adverse events most commonly observed after CAR-T therapy, the management of CRS and ICANS, and the prophylaxis and treatment of infectious complications.

5. Follow-up
Hospitalisation after infusion, long-term patient monitoring, and the division of responsibilities between the CAR-T centre and the referring centre.

Expert closing remarks
Key practical takeaways for centres starting CAR-T therapy and experience with bispecific therapies after CAR-T.

Live audience Q&A (approx. 30 minutes)
Questions submitted by participants via chat, answered by the panelists in real time.

Closing: live audience Q&A
Questions submitted by participants via chat, answered by the experts in real time. The discussion will also cover practical advice for physicians starting out with CAR-T therapy and experience with bispecific therapies in subsequent lines of treatment.